Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2271 - Impact of Immune response-associated gene Polymorphisms on tumor response in Rectal Cancer Patients Treated with capecitabine +/- oxaliplatine and Radiation in the ACCORD-12/PRODIGE-2 phase III trial

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Translational Research;  Colon and Rectal Cancer

Presenters

Boige Valerie

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

B. Valerie1, C. Mollevi2, N. Chaput3, S. Gourgou2, D. Azria4, J.F. Seitz5, L. Bigot6, B. Juzyna7, I. Miran8, J. Gérard9, P. Laurent-Puig10

Author affiliations

  • 1 Oncologic Medicine, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 2 Biostatistics, Institut du Cancer de Montpellier, 34298 - Montpellier/FR
  • 3 Immunology, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 4 Radiotherapy, Laboratoire de Radio-Analyse du C.R.L.C., 34298 - Montpellier/FR
  • 5 Gastroenterology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 6 Inserm U981, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 7 R&d Unicancer, Unicancer, 75654 - Paris/FR
  • 8 Translational Research, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 9 Radiothérapie, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR
  • 10 Department Of Biology, Paris Descartes University, 75006 - Paris/FR
More

Resources

Abstract 2271

Background

We examined whether 133 germline polymorphisms (SNPs) in 15 candidate genes (CSF1R, IL8RA, TLR4, IL10, IL10RA, CTLA4, IL2, IL2RA, TGFb1, ICOS, IL13, IL13RA2, IFNgR, IL15 and IL15RA) would predict clinical outcome in the ACCORD-12 phase III trial which randomly compared neoadjuvant radiotherapy (RT) plus capecitabine (CAP45) with dose-intensified RT plus capecitabine and oxaliplatin (CAPOX50) in T3-4 Nx M0 resectable rectal cancer.

Methods

A candidate-gene association study was conducted in 316 patients (n = 161 in the CAPOX50 and n = 155 in the CAP45 arm). The primary end-point was tumor response according to the Dworak score in each arm. Logistic regressions were used to assess uni/multivariate associations. The Storey and Tibshirani method based on the control of false discovery rate was used (q-value

Results

In univariate analysis, two SNPs in IL2RA (rs11256456: OR = 5.1 [2.38; 11] and rs706781: OR = 4.2 [1.98; 8.74]) were significantly associated with the Dworak score in the CAP45 arm, and one in IL2RA the CAPOX50 arm (rs2104286: OR = 0.11 [0.01; 0.90]. All were confirmed in the multivariate analysis. Patients were categorized into 3 haplotype groups after the haplotype analysis of IL2RA rs11256456 and rs706781: one had a positive prognostic effect on tumor response in the CAP-45 arm (OR = 3.85 [1.97; 7.53], p = 0.0001) and in the overall population (OR = 1.76 [1.15; 2.68], p = 0.009). Interaction was also significant, suggesting a predictive positive effect of the same haplotype for response to CAP-45 (OR = 4.12 [1.71, 9.94], p = 0.002). None of the three IL2RA SNPs were correlated with survival in the multivariate analysis.

Conclusions

This pharmacogenetic analysis shows that SNPs in IL2RA are significantly associated with response to neoadjuvant chemoRT in patients with locally advanced rectal cancer. Their predictive effect may identify patients who benefit from CAP-45.

Clinical trial identification

Legal entity responsible for the study

UNICANCER

Funding

INCA-RT

Disclosure

B. Valerie: Consulting or/and advisory roles for Merck Serono, Amgen, Sanofi-Aventis, Prestizia and Bayer; honoraria from Amgen, Merck Serono, Roche, Novartis and Bayer; research funding from Merck Serono. J.F. Seitz: Grants for consultancy for Celgene, Lilly, Merck, Novartis Oncology, Pfizer, Sanofi, Roche; grants from Roche; payments for development of educational presentations for Amgen and Lilly. P. Laurent-Puig: Consulting or/and advisory boards for Sanofi, Merck KGaA, Amgen, Roche, Genomic Health, Myriad Genetics and Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.